Chuanbeinone


CAS No. : 103530-47-8

(Synonyms: 22-Epidelavinone)

103530-47-8
Price and Availability of CAS No. : 103530-47-8
Size Price Stock
100 mg Get quote
250 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-107272
M.Wt: 413.64
Formula: C27H43NO2
Purity: >98 %
Solubility:
Introduction of 103530-47-8 :

Chuanbeinone (22-Epidelavinone) is an orally active alkaloid found in Fritillaria pallidiflora. Chuanbeinone shows cytotoxicity against mutiple cancer cells and can induces apoptosis and S phase arrest. Chuanbeinone downregulates Bcl-2, upregulates Bax, and activates caspase-3. Chuanbeinone exerts anti-inflammatory and antitussive effects by reducing pro-inflammatory cytokine (IL-1β, IL-6 and TNF-α) production and mRNA expression, and inhibiting TRIF-, MyD88-, NF-κB-, and MAPK-dependent signaling pathways. Chuanbeinone inhibits AChE and BChE with IC50 values of 7.7 and 0.7 μM. Chuanbeinone can be used for the researches of lung carcinoma, cough, inflammatory diseases[1][2][3][4]. In Vitro:Chuanbeinone inhibits the growth of LLC, A2780, HepG2, and A549 cells with IC50 values of 10.51 μg/mL, 18.16 μg/mL, 37.97 μg/mL, and 43.74 μg/mL, respectively[1].
Chuanbeinone (5-15 μg/mL; 48 h) induces dose-dependent apoptosis in LLC cells, with apoptotic rates of 12.8% to 64.8%[1].
Chuanbeinone (10 μg/mL; 24-72 h) induces time-dependent S phase arrest and decreases the cells in the G0/G1 phase[1].
Chuanbeinone (5-15 μg/mL; 48 h) downregulates Bcl-2, upregulates Bax, and activates caspase-3 in LLC cells[1].
Chuanbeinone (20-100 μM; 24 h) reduces RAW 264.7 cell viability[2].
Chuanbeinone (5-20 μM; 24 h, co-treated with 0.2 μg/mL LPS) exerts anti-inflammatory effects on LPS (HY-D1056)-induced RAW 264.7 cells by reducing pro-inflammatory cytokine production and mRNA expression, and inhibiting TRIF-, MyD88-, NF-κB-, and MAPK-dependent signaling pathways[2].
Chuanbeinone inhibits AChE with an IC50 of 7.7 ± 0.001 μM and BChE with an IC50 of 0.7 ± 0.001 μM, and exhibits 70.7 ± 3.3% enzyme inhibition at 100
μM[3]. In Vivo:Chuanbeinone (10-40 mg/kg; p.o.; daily; 10 days) exhibits significant antitumor activity in LLC-bearing C57BL/6J and S180-bearing ICR mice, inducing tumor growth inhibition, apoptosis, and angiogenesis inhibition[1].
Chuanbeinone (1.5-3.0 mg/kg; p.o.; single dose) exhibits dose-dependent antitussive effects in ammonia-induced cough in Mus musculus, with 3.0 mg/kg producing a 60.49% inhibition of cough frequency[4].
Chuanbeinone (3.0 mg/kg; p.o.; single dose) does not exhibit significant expectorant activity in the tracheal phenol red secretion model in mice[4].
Chuanbeinone (1.5-3.0 mg/kg; p.o.; single dose) exhibits anti-inflammatory effects at 3.0 mg/kg in xylene-induced ear edema in Mus musculus[4].

Your information is safe with us.